Bistrimate1 (Sodium Bismuth Triglycollamate) Administered by Mouth in the Treatment of Chronic Discoid Lupus Erythematosus21Bistrimate Tablets for this study were kindly supplied by Carroll Dunham Smith Pharmacal Company, New Brunswick, New Jersey.2From The New York Skin and Cancer Unit, Department of Dermatology and Syphilology of the New York Post Graduate Medical School and Hospital, Dr. Marion B. Sulzberger, Director. Preliminary Report by Sawicky, H.H.
BISTRIMATE* (SODIUM BISMUTH TRIGLYCOLLAMATE)
ADMINISTERED BY MOUTH IN THE TREATMENT OF
CHRONIC DISCOID LUPUS ERYTHEMATOSUS**
PRELIMINARY REPORT
H. H. SAWICKY, M.D.
Bismuth is widely employed in the treatment of lupus erythematosus and is generally
accepted as a valuable agent in the management of this disease. Following reports (1) of
the high therapeutic efficiency and relatively low toxicity of Bistriniate, and because of the
ease of administration, the present study was undertaken.
PIIABMAc0L0uY
Each tablet of Bistrimate contains 410 mg. of sodium bismuth triglycollamate equivalent
to 75 mg. of metallic bismuth. It occurs as a white powder which dissolves readily in water
to give a solution which is approximately neutral in reaction. It is adequately absorbed
from the gastrointestinal tract with relatively little local irritation and is rapidly and
completely excreted in the urine (2, 3).
CLINIcAL 5flIIES
Sodium bismuth triglycollamate was administered three times daily in doses of 1 tablet
after each meal for the first three days and two tablets after each meal thereafter. The
present report deals with a series of thirty unselected cases of lupus erythematosus treated
for periods ranging from 4 to 26 weeks. No additional form of therapy was used during
the period of study. Of the thirty subj ects, varying in age between 23 and 62, eighteen were
white females, two colored females and ten white males. Eight had the disease for 6 months
or under; eleven, between 6 months and two years; and eleven, for periods of time between
two and twenty-five years. All of the twenty two cases, having the disease for 6 months
or over, had previously received varying numbers of intramuscular injections of a prepara-
tion of bismuth in oil with equivocal results. Twenty two of the cases were classified as
chronic discoid in type; two seborrheic in type; four chronic disseminated discoid; and one
each telangiectatic and sub-acute disseminated lupus erythematosus.
Thc response to treatment was considered good to excellent if the cutaneous manifesta-
tions either disappeared completely or almost completely. Otherwise the response was
graded 'fair' or 'poor.' Of the eight patients who had the disease for 6 mo. or under, in
five the results were rated good to excellent; and in three fair to good. Of the remaining
twenty two, eleven had good to excellent results; six fair to good; and in five the results were
poor or lacking. The one sub-acute disseminated case improved under therapy and then
relapsed when therapy was discontinued because of a toxic reaction (see below). Addi-
tional relapses are anticipated but none have been observed up to the present time.
TOXIC REAcTIoNS
A bismuth line, mild gastro-intestinal upsets, and mild headache, observed with some
frequency, were not considered contra indications to continuation of therapy. Two pa-
tients, including the aforementioned sub-acute disseminated case, presented a stomatitis
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with trigeminal neuralgia severe enough to warrant cessation of therapy. Two others
developed a severe stomatitis but tolerated reduced doses of the drug. One subject com-
plained of muscular pains in all four extremities, and after a rest period of two weeks, re-
sumed treatment without untoward effect.
Repeated urine examinations failed to reveal any evidence of renal irritation.
Complete blood counts were made prior to initiation of therapy and every two weeks
thereafter during the period of treatment. A transient leukopenia was observed in three
patients but the blood pictures returned to normal in spite of continuation of therapy.
DIscussIoN
Thirty unselected cases of lupus erythematosus were treated with oral administrations
of sodium bismuth triglycollamate (Bistrimate). Twenty two of the patients had previ-
ously been treated with bismuth by intramuscular injection. Results were rated good to
excellent in sixteen subjects, fair to good in nine, and poor to lacking in five. In only two
cases was it considered advisable to discontinue the drug because of a toxic reaction (severe
stomatitis with trigeminal neuralgia in each case).
coNcLusIoNs
Sodium bismuth triglycollamate (Bistrimate) by mouth is at least as effective as paren-
teral bismuth therapy in the treatment of chronic discoid lupus erythematosus. Failure
to respond to parenteral bismuth therapy is not a contraindication to Bistrimate therapy.
Treatment with Bistrimate, in doses of 1—2 tablets (75—150 mg. of metallic bismuth) three
times daily for as long as 26 weeks appears to be a relatively safe procedure. Ease of ad-
ministration, relative safety and relative efficacy would appear to make Bistrimate therapy
the treatment to be tried first in chronic discoid lupus erythematosus.
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